8673927 May 4, 2027PED: Nov 4, 2027 PED — — U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN Delisted 8883805 Nov 26, 2025PED: May 26, 2026 PED — Yes — — 9155705 May 21, 2030PED: Nov 21, 2030 PED — Yes — — 9173859 May 4, 2027PED: Nov 4, 2027 PED — Yes U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN Delisted 9415016 Apr 2, 2029PED: Oct 2, 2029 PED — Yes — — 9555001 Mar 6, 2033PED: Sep 6, 2033 PED — Yes U-1967 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN — 10022379 Apr 2, 2029PED: Oct 2, 2029 PED — — U-2339 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS — 11911388 Apr 10, 2030 — — — U-3854 LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN — 12364700 Jun 8, 2037PED: Dec 8, 2037 PED — — U-4224 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN —